SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

Study of TFX06 in Women With Advanced Breast Cancer.

NCT05927779 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors

NCT06503783 ·Status: RECRUITING ·Phase: PHASE1

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

NCT05429684 ·Status: UNKNOWN ·Phase: PHASE3

Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

NCT05860465 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer

NCT05077449 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors

NCT06299124 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

NCT05635487 ·Status: RECRUITING ·Phase: PHASE2

SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response

NCT07129187 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

NCT03471663 ·Status: COMPLETED ·Phase: PHASE1

A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors

NCT04446260 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer

NCT00627627 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers

NCT05349409 ·Status: UNKNOWN ·Phase: PHASE2

Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer

NCT04158505 ·Status: UNKNOWN

A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer

NCT05629949 ·Status: COMPLETED ·Phase: PHASE3

Real World Study on the Efficacy and Safety of Anti-HER2 Therapy

NCT05367739 ·Status: COMPLETED

A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer

NCT06954961 ·Status: RECRUITING ·Phase: PHASE3

A Study of A166 in Patients With Advanced Solid Malignant Tumors

NCT05311397 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer

NCT06057610 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

NCT05744687 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour

NCT06915142 ·Status: RECRUITING ·Phase: PHASE2

A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

NCT05514717 ·Status: RECRUITING ·Phase: PHASE1

A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer

NCT05945927 ·Status: COMPLETED

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

NCT06210776 ·Status: RECRUITING

Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer

NCT07180082 ·Status: RECRUITING ·Phase: PHASE2

The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.

NCT05263570 ·Status: RECRUITING